GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Angelo Maria Patti, Giuseppe Montalto, Manfredi Rizzo, Dragana Nikolic, Manfredi Rizzo, Brooke S. Mcadams, Francesco Cosentino, Ali A. Rizvi, Manfredi Rizzo, Carlo Mannina

Risultato della ricerca: Articlepeer review

25 Citazioni (Scopus)

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially preventing CV events. In fact, the introduction of IBTs is one of the key moments in the history of diabetes research and treatment. Such therapeutic strategies allow customization of antidiabetic treatment to each patient's need and therefore obtain better metabolic control with reduced CV risk. The aim of the present paper is to provide a comprehensive overview of the effects of GLP-1RA on various cardiometabolic markers and overall CV risk, with particular attention on recent CV outcome studies and potential mechanisms. In particular, the effects of liraglutide on formation and progression of atherosclerotic plaque and mechanisms explaining its cardioprotective effects are highlighted.
Lingua originaleEnglish
pagine (da-a)2814-2821
Numero di pagine8
RivistaBIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE
Volume1864
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology

Fingerprint Entra nei temi di ricerca di 'GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms'. Insieme formano una fingerprint unica.

Cita questo